Apogee Therapeutics, Inc. Common Stock Cash Flow-to-Debt Ratio
Apogee Therapeutics, Inc. Common Stock cash flow-to-debt ratio. Apogee Therapeutics, Inc. Common Stock (APGE) has a Cash Flow-to-Debt Ratio of -0.51x as of June 2026, meaning its operating cash flow of $-71.38 Million could theoretically repay -1% of its total liabilities ($141.21 Million) in one year. See financial agility of Apogee Therapeutics, Inc. Common Stock to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Apogee Therapeutics, Inc. Common Stock (2022–2025)
Cash flow-to-debt ratio of Apogee Therapeutics, Inc. Common Stock from 2022 to 2025. Historical debt coverage capacity for Apogee Therapeutics, Inc. Common Stock across 4 annual periods. Also explore net asset momentum of Apogee Therapeutics, Inc. Common Stock to track the company's year-over-year net asset growth rate.
Apogee Therapeutics, Inc. Common Stock Cash Flow-to-Debt Ratio by Year (2022–2025)
Apogee Therapeutics, Inc. Common Stock cash flow-to-debt ratio by year from 2022 to 2025. Year-by-year debt coverage analysis for Apogee Therapeutics, Inc. Common Stock. For the full cash flow conversion analysis, see how efficiently does Apogee Therapeutics, Inc. Common Stock generate cash.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -6.84x | $-227.45 Million | $33.25 Million | ▼ -48.5% |
| 2024 | -4.61x | $-171.17 Million | $37.16 Million | ▼ -32.4% |
| 2023 | -3.48x | $-74.76 Million | $21.49 Million | ▼ -111.3% |
| 2022 | -1.65x | $-16.43 Million | $9.98 Million | — |